Castrate-Sensitive Prostate Cancer: Treatment Planning


The importance of risk stratifying patients with hormone-sensitive prostate cancer, and recommendations for germline and somatic testing.

Nicholas Vogelzang, MD, FASCO, FACP: If we think about using a full androgen receptor-targeted therapy, in this case we are getting the leuprolide and apalutamide regimen, that gives us options for care. When he relapses, which is hopefully not for a long time, we still have docetaxel, we have radium, and we have sipuleucel-T. I should also mention that this patient should have at least some attempt made to obtain BRCA-targeting data. We should know whether he has PARP inhibition therapy options. I always tend to get germline testing and somatic testing done. I routinely get germline testing done, and I get somatic testing done on the tissue itself, so if he relapses down the road, then I have the opportunity for both olaparib and rucaparib therapies, depending upon which DNA repair deficiency enzyme the patient has. For example, I saw a patient the other day who has Bloom syndrome, and he has a rapid PSA [prostate-specific antigen] doubling time, so I am preparing to give him olaparib if his symptoms rapidly worsen. That is the treatment planning sequence, if you will.

Transcript edited for clarity.

Case: A 76-Year-Old Male With Recurrent Castrate-Sensitive Prostate Cancer


  • A 76-year-old man diagnosed with localized prostate cancer, 4 years ago
  • At that time, he underwent EBRT


  • Patient was lost to follow-up; returns due to intermittent hip pain
  • PMH: obese, BMI 32; prostate cancer; otherwise unremarkable
  • FH: No known family history of cancer
  • PE: left hip tender to palpation, slight limp and evidence of decreased weight bearing on left lower limb

Clinical workup

  • PSA 10 ng/mL; doubling time 3 months
  • Core needle biopsy with TRUS showed adenocarcinoma of prostate
    • Gleason score (4+4)
    • Bone scan revealed 2 bone metastases: 1 in the left femur 1 in the left pelvis
  • Chest/abdominal/pelvic CT scan positive for 4 pelvic lymph node metastases
  • Diagnosis: stage IV mCSPC
  • ECOG PS 1

Treatment and Follow-Up

  • He was started on ADT + apalutimide 240 mg qDay
  • At 3-month follow up: PSA 2 ng/mL
  • Repeat imaging showed no new lesions

Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content